Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316182 | 1.00 | ALDH1A1 (0.36) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL24316185 | 0.98 | ALDH1A1 (0.37) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL27010019 | 0.93 | ALDH1A1 (0.41) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL27010023 | 0.88 | EPHX1 (0.38) | ALDH1A1EPHX1 | |
| SCHEMBL26239730 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL26618316 | 0.78 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTRORCMEN1 | |
| SCHEMBL24317289 | 0.78 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTRORCMEN1 | |
| SCHEMBL27010021 | 0.77 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL26618313 | 0.76 | KMT2A (0.38) | ALDH1A1LMNAPER2CRY1CRY2 | |
| SCHEMBL24316189 | 0.75 | CYP1A2 (0.39) | RORCADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ALDH1A1 2267/4885LMNA 3978/4885PER2 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.